Payment overview · 2025
General Payments
$60.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Nanda D Ramsaroop, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MINEOLA, NY · NPI 1922048032
Verified facts
What the public records show
CMS Open Payments records show Nanda D Ramsaroop, MD received $60.00 in general payments during 2025 across 1 reported records.
Astellas Pharma US Inc accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $60.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 245 | 67 |
| Losartan Potassium | Losartan Potassium | 219 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 66 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 54 |
| Omeprazole | Omeprazole | 152 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 143 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 34 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 31 |
| Gabapentin | Gabapentin | 82 | 36 |
| Famotidine | Famotidine | 75 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 27 |
| Eliquis | Apixaban | 68 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 24 |
| Lisinopril | Lisinopril | 63 | 15 |
| Azithromycin | Azithromycin | 60 | 47 |
| Simvastatin | Simvastatin | 58 | 15 |
| Farxiga | Dapagliflozin Propanediol | 54 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 11 |
| Glimepiride | Glimepiride | 52 | 14 |
| Trazodone Hcl | Trazodone Hcl | 52 | 11 |
| Azelastine Hcl | Azelastine Hcl | 51 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 13 |
| Atenolol | Atenolol | 46 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 34 |
| Jardiance | Empagliflozin | 44 | 14 |
| Meloxicam | Meloxicam | 44 | 16 |
| Furosemide | Furosemide | 43 | 16 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 24 |
| Montelukast Sodium | Montelukast Sodium | 37 | 12 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $60.00 · 1 records | Astellas Pharma US Inc | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error